Caris Life Sciences partners with Merck KGaA to discover cancer targets and fast-track ADC development

Ipsen licenses Sutro ADC in $900m deal

Datopotamab deruxtecan BLA accepted in the US for patients with previously treated metastatic HR-positive, HER2-negative...

Adcentrx Therapeutics to showcase Preclinical findings of Nectin-4 ADC Program at AACR Annual Meeting 2024